Everest Medicines (01952) has announced that the National Medical Products Administration (NMPA) of China has approved a new 100mg strength of Xerava (eravacycline for injection).
Xerava is the world's first and only fully synthetic fluorocycline antibacterial agent (as of November 2026), characterized by a broad antibacterial spectrum, strong antibacterial activity, demonstrated clinical efficacy, and a favorable safety profile. It has been recommended by multiple domestic and international guidelines and consensus statements for the empirical treatment of complicated intra-abdominal infections (cIAI), as well as a clinical option for treating multidrug-resistant bacterial infections.
The 50mg strength of Xerava was approved in China in 2023 for the treatment of complicated intra-abdominal infections in adults. The approval of this 100mg strength represents an important milestone for the company in refining its product portfolio and expanding commercial potential, reflecting its commitment to addressing clinical needs and efficiently advancing product registration.
Xerava employs a weight-based dosing regimen, with a recommended dose of 1mg/kg administered every 12 hours. The addition of the 100mg strength provides clinicians with a more flexible and convenient dosage option, helping to reduce drug preparation procedures and liquid waste during treatment for some patients, further enhancing clinical convenience. Meanwhile, the approval of the 100mg strength will further strengthen the supply assurance capability of Xerava in the Chinese market to better meet clinical demand.
The company's global manufacturing base in Jiashan has obtained a production license, ensuring supply stability from the source. The company is actively advancing the localization of Xerava production, with technology transfer progressing smoothly; the 50mg formulation of Xerava has completed process validation. Leveraging the Jiashan manufacturing base, the company continues to build and upgrade production capacity, accelerating the localization of commercialized innovative products such as Velsipity and Xervate within its core therapeutic portfolio, while simultaneously advancing active pharmaceutical ingredient (API) production layout and continuously improving the production system from API to finished drug.
In the future, the Jiashan manufacturing base will further enhance capacity allocation and production supply coordination, strengthening supply chain stability and resilience to support the company's long-term development. Xerava (eravacycline for injection) is the world's first fluorocycline antibacterial agent, indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults, with broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria, Gram-positive bacteria, anaerobes, and atypical pathogens.
Xerava has been recommended by multiple global treatment guidelines, including the Surgical Infection Society (SIS) Guidelines for the Management of Intra-Abdominal Infections, the Infectious Diseases Society of America (IDSA), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), as a treatment option for multidrug-resistant Gram-negative bacterial infections, including carbapenem-resistant infections. It has also been recommended by China's Expert Consensus on Multidisciplinary Diagnosis and Treatment of Common Surgical Intra-Abdominal Infections and the Guidelines for the Diagnosis, Treatment, and Prevention of Carbapenem-Resistant Gram-Negative Bacterial Infections.
Xerava has been approved for marketing in the United States, the European Union, the United Kingdom, Singapore, and Hong Kong, China. In March 2023, the NMPA of China formally approved the new drug application for Xerava, and it was successfully commercialized in mainland China in July of the same year, providing a new treatment option for Chinese patients with complicated intra-abdominal infections.
Comments